Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...

Key Presentations and Symposia: Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) announced upcoming data presentations and programming at ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

England's drug-cost regulator rejcted Eli Lilly's Alzheimer's drug for use in the country's public health system, marking the second time a treatment for the disease has been deemed too costly.

The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”. The news ...

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...